Status:
COMPLETED
A Dose Escalation Study of the Safety and Pharmacokinetics of GSK1363089 (Formerly XL880) Administered Orally Daily to Subjects With Solid Tumors
Lead Sponsor:
GlaxoSmithKline
Conditions:
Solid Tumours
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
This clinical study is being conducted at two sites to determine the optimum dose, safety, and tolerability of oral daily GSK1363089 treatment in adults with solid tumors. This study is no longer recr...
Eligibility Criteria
Inclusion
- Histologically confirmed solid tumor which is metastatic or unresectable with no known effective treatment measures,
- ECOG performance status of \</= 2.
- Adequate bone marrow reserve, hepatic, renal, and cardiovascular function,
- Negative pregnancy test.
Exclusion
- Anticancer therapy within 30 days of the start of treatment,
- Received radiation to =25% of bone marrow within 30 days of treatment.
- Known brain metastasis,
- Uncontrolled intercurrent illness,
- HIV positive,
- Pregnant or breastfeeding women.
Key Trial Info
Start Date :
August 9 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 9 2009
Estimated Enrollment :
37 Patients enrolled
Trial Details
Trial ID
NCT00743067
Start Date
August 9 2006
End Date
November 9 2009
Last Update
July 26 2017
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.